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Abstract
Colchicine is a potent antimitotic poison which is well known to prevent microtubule assembly by binding tubulin very
tightly. Colchicine also possesses anti-inflammatory properties which are not well understood yet. Here we show that
colchicine tightly interacts with lipid layers. The physical and biological properties of three different lipid derivatives of
colchicine are investigated parallel to those of membrane lipids in the presence of colchicine. Upon insertion in the fatty alkyl
chains, colchicine rigidifies the lipid monolayers in a fluid phase and fluidifies rigid monolayers. Similarly X-ray diffraction
data show that lecithin^water phases are destabilized by colchicine. In addition, an unexpectedly drastic enhancement of the
photoisomerization rate of colchicine into lumicolchicine in the lipid environment is observed and further supports insertion
of the alkaloid in membranes. Finally the interaction of colchicine with lipids makes the drug inaccessible to tubulin. The
possible in vivo significance of these results is discussed. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Colchicine, a heterocyclic alkaloid isolated from
Colchicum automnale [1], is a well known antimitotic
poison (Fig. 1) and is also commonly used for its
anti-in£ammatory properties. Its antitumor activity
derives from its tubulin binding activity [2,3]. Colchi-
cine binds speci¢cally to tubulin KL heterodimers
with a high a⁄nity [4,5]. Extensive studies on the
kinetics of tubulin^colchicine binding have indicated
that the binding reaction occurs as a two step pro-
cess, the initial fast and reversible bimolecular bind-
ing reaction being followed by a slow monomolecu-
lar reaction [6^10]. The resulting 1/1 tight complex
dissociates very slowly [11^13]. The binding of col-
chicine to tubulin induces a GTPase activity at the E-
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site (L tubulin) [14]. Colchicine binding is linked to a
conformational change of tubulin dimers which in-
hibits their assembly into microtubules both in vivo
and in vitro [7,14^23]. However, the tubulin^colchi-
cine complex binds actively to microtubule ends in
an end poisoning fashion and can be incorporated,
to a low extend, into microtubules [24^26], pending
an appreciable loss in stability. In addition, the tu-
bulin^colchicine complex can self-assemble into non
microtubular polymers with thermodynamic charac-
teristics similar to those of microtubules [20,22]. The
atomic structure of the KL tubulin dimer has been
solved by electron crystallography of Zn-induced tu-
bulin sheets [27]. An atomic model of the microtu-
bule has recently been proposed [28,29]. The colchi-
cine binding site on the L subunit, in close proximity
of the nucleotide E-site, accounts for the biochemical
properties of tubulin^colchicine. Although colchicine
is a water soluble compound and shows a high a⁄n-
ity and selectivity for tubulin, di⁄culties have been
met in its clinical use, suggesting that other unknown
targets might interfere with tubulin binding.
In the course of our work on the two-dimensional
crystallization of the tubulin^colchicine complex on
lipid layers at the air^water interface, we examined
the possibility to immobilize the protein at mono-
layers spread from colchicine-anchored lipids. We
faced di¡erent problems that led us to investigate
into details the colchicine^lipid and tubulin^colchi-
cine interactions. A set of water soluble and lipid
derivatives of colchicine has been prepared and here-
in we present a series of protein binding experiments,
spectroscopic measurements, X-ray di¡raction and
transmission electron microscopy data that provide
strong evidence for the tight interaction of colchicine
with lipid boundaries. The results are discussed in
view of the technical problems linked to the under-
standing of the in vivo e¡ects of colchicine.
2. Materials and methods
2.1. Chemicals
Compounds 1^10 (Fig. 1) were synthesized as de-
scribed elsewhere [30,31].
Firstly, four colchicinoids (compounds 1^4), di¡er-
ing in their hydrophobicity, were prepared in order
to check whether structural modi¢cations at the B-
ring have crucial in£uence on the complexation of
the alkaloid by tubulin. The original acetyl group
on the B-ring of colchicine has been replaced by
either a N-acyl linker (compounds 1 and 2) or a N-
alkyl linker (compounds 3 and 4). To decrease the
hydrophobicity of the close neighborhood of the
modi¢ed alkaloid, a hydrophilic ether function has
been introduced in the linker chain (compounds 2
and 4). The hydrophilicity of the compounds in-
creases from 1 to 4, and compound 1 will be referred
to as the more hydrophobic colchicinoid while 4 will
be referred to as the more hydrophilic one. In all
cases, the linker is terminated with a benzyl group
in order to sterically mimic the later attached lipid.
Many properties of these compounds are similar.
Fig. 1. Chemical structures of colchicine and colchicine deriva-
tives analyzed in the present work. Four water soluble deriva-
tives of colchicine have been studied (1^4). The initial N-acetyl
group on the B-ring in colchicine is replaced with either a N-
acyl linker (compounds 1 and 2) or an N-alkyl linker (com-
pounds 3 and 4). Linkers are terminated with a benzyl group
so as to sterically mimic the bottom part of the further lipids
(see 5^7). Introduction of an additional ether function in the
linker chain (compounds 2 and 4) aimed to decrease the hydro-
phobicity in the close neighborhood of the modi¢ed alkaloid.
Three di¡erent lipid derivatives of colchicine (5^7) were used to
investigate the possible insertion of colchicine into lipid aggre-
gates (monolayers or vesicles) and the interaction between tubu-
lin and colchicine in a hydrophobic environment. Some of them
were used as mixtures with diluting lipids 8^10.
BBAMEM 77939 25-9-00
S. Mons et al. / Biochimica et Biophysica Acta 1468 (2000) 381^395382
Therefore, for the sake of clarity, we will refer to
these molecules as colchicinoids, unless di¡erences
have to be described.
Secondly, colchicinoids were chemically bound to
di¡erent lipid structures. That was required for fur-
ther two-dimensional crystallization trials with the
microtubule component. In order to provide the col-
chicinoid with su⁄cient accessibility, three oxyethy-
lene units were inserted as a linker between the alka-
loid and the lipid moieties (compounds 5^7). The
aliphatic chains of the lipids are either unsaturated
(compounds 5 and 6) or saturated (compound 7).
Due to the intrinsic mechanical properties of the
compounds resulting from the structure of the
chains, these lipids will be referred to as the £uid
neutral (5), £uid-charged (6), and rigid neutral (7)
colchicinoid-anchored lipids. MES was purchased
from Calbiochem; PIPES and EGTA were from Sig-
ma; colchicine was from Prolabo; DMPC, DOPC,
eggPE-£uorescein and DPPE-rhodamine B were
from Avanti Polar Lipids.
2.2. Tubulin puri¢cation
Tubulin was puri¢ed from pig brain through three
cycles of assembly^disassembly according to Shelan-
ski [32] followed by phosphocellulose chromatogra-
phy [33] in 25 mM MES pH 6.8, containing 0.125
mM MgCl2 and 0.25 mM EGTA. Pure tubulin was
concentrated by ultra¢ltration (Amicon) and stored
at 380‡C in 50 mM MES pH 6.8, 3.4 M glycerol,
0.5 mM MgCl2, 1 mM EGTA, and 0.1 mM GTP
(bu¡er A).
2.3. Binding of colchicine and colchicinoids to tubulin
Binding of colchicine and colchicinoids to tubulin
was monitored by the associated increase of the col-
chicine £uorescence [7,13]. Tubulin was equilibrated
in 0.1 mM PIPES pH 6.8, 1 mM MgCl2, 1 mM
EGTA, 0.1 mM GTP (bu¡er B) by Sephadex G-25
chromatography (PD-10, Pharmacia). Binding assays
were then typically performed at 37‡C with a 3^5 WM
colchicine concentration. The time course of £uores-
cence change was monitored with a Spex Fluorolog
2, equipped with a shutter that was closed between
measurements in order to prevent bleaching of the
sample.
2.4. Polymerization of tubulin^colchicine and
tubulin^colchicinoid complexes
The kinetics of assembly of tubulin^alkaloid com-
plexes was monitored turbidimetrically as previously
described [34]. Formation of the tubulin^colchicine
(or tubulin^colchicinoid) complex was carried out
by incubating tubulin (62 WM) with 250 WM colchi-
cine (or colchicinoid) in bu¡er A at 37‡C for 30 min,
followed by removal of the free ligand by activated
charcoal (3 mg/ml) and rapid centrifugation in an
Eppendorf microcentrifuge. The tubulin concentra-
tion was determined by UV absorption as previously
described [35]. The concentration of bound ligand
was determined spectrophotometrically using an ex-
tinction coe⁄cient of 16 600 M31 cm31 at 350 nm.
One molecule of colchicine was found to be bound
per tubulin dimer.
Polymerization of tubulin^colchicine and tubulin^
colchicinoid complexes was monitored at 37‡C in
bu¡er A supplemented with 1 mM GTP and 10
mM MgCl2. The critical concentration for assembly
was determined by measuring the concentration of
unpolymerized tubulin present in the supernatant of
samples centrifuged at 400 000Ug, at 37‡C for 5 min
at the end of the assembly process.
2.5. GTP hydrolysis measurements
The rate of GTP hydrolysis by tubulin^colchici-
noid complexes was assayed as previously described
[20] in bu¡er A containing 0.625 mM Q-32P-labeled
GTP at 37‡C. The concentration of the tubulin^col-
chicine and tubulin^colchicinoid complexes was 15
WM.
2.6. Colchicine and colchicinoids photoisomerization
experiments
The method previously described by Roigt and
Leblanc was used [36]. The isomerization reaction
was monitored by measuring the optical density at
350 nm, corresponding to the absorption of the tro-
pone moiety which is absent in lumicolchicines. The
residual absorption coe⁄cient of lumicolchicines at
this wavelength has been determined to be 1650 cm31
M31, i.e. 1/10 that of colchicine [37]. Colchicine sam-
ples were prepared either in water, methylene chlo-
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ride or hexane/ethanol (9/1; v/v) at a concentration
of 51 WM. Colchicinoid-anchored lipid 5 was solubi-
lized in hexane/ethanol (9/1; v/v), at the same con-
centration. Spectra were recorded on a Hewlett Pack-
ard 8452A diode array spectrophotometer using 1 cm
quartz cuvettes. Photoisomerization experiments
were realized with samples in the same quartz cuv-
ettes, using a bench UV-lamp (Bioblock Scienti¢c,
365 nm, 6 W).
2.7. Film balance experiments
Surface pressure isotherms of the colchicinoid-an-
chored lipids were measured using a home-made
Langmuir trough made of aluminum covered with
Te£on (76.8U253.4 mm). Surface pressure was mea-
sured with a Wilhelmy plate coupled to a linear
transducer as previously described by Albrecht [38].
Monolayers were spread from 0.5 mM lipid solutions
in hexane/ethanol (9/1; v/v). Volumes ranging from
100 to 300 WM were delivered at several locations
across the water surface with a Hamilton microsyr-
inge. At least 15 min were allowed for the spreading
solvent to evaporate before monolayer compression.
The subphase consisted of puri¢ed water (pH 5.35,
Millipore ¢ltration system, Barnstead, NANO pure
11) with a resistivity of 18.2 106 6cm. Surface pres-
sure versus molecular area curves were recorded at
21.0 þ 0.2‡C with a compression speed of 2^5 Aî 2 per
lipid molecule per minute. All measurements were
carried out in triplicate. Speci¢c areas As, lift-o¡
areas Alo, and collapse pressures Zc were determined
as previously described [39].
2.8. Fluorescence microscopy of the monolayers
Fluorescence microscopy experiments were per-
formed on a dedicated ¢lm balance of local design
equipped with a Nikon epi£uorescence microscope.
This equipment is very similar to that used by Meller
[40], and has been thoroughly described elsewhere
[41]. Colchicinoid-anchored lipid samples containing
either eggPE-£uorescein or DPPE-rhodamine B (1
mol%) were spread on pure water (pH 5.35, 21‡C).
After spreading, the lipid layers were in the gas-ana-
log state (2^5 nm2/molecule) and were observed with
a SIT camera attached to the microscope. The im-
ages were recorded on a videotape and printed by a
Sony video printer.
2.9. Tubulin binding to colchicinoid-anchored lipid
layers
All the experiments were carried out under red
light to avoid photodegradation of the alkaloid
bound to the lipids. Typically, bu¡er B (13 Wl) was
placed in a small Te£on well (4 mm diameter, 1 mm
deep) and a colchicinoid-anchored lipid (5^7, 1 Wl,
0.5 mg/ml in hexane/ethanol 9/1; v/v) was spread at
the surface of the aqueous solution. The spreading
solvent was allowed to evaporate for 15 min before
tubulin (4 Wl, 4 mg/ml in bu¡er B) was injected be-
neath the lipid layer. The whole device was sealed to
prevent water evaporation and stored in the dark.
The protein was allowed to incubate with the lipid
¢lm over periods ranging from a few minutes to sev-
eral hours at 4, 20, or 37‡C. The lipid layer and the
bound protein were picked up onto a carbon-coated
electron microscopy grid, negatively stained with ur-
anyl acetate, and examined on a CM12 (Philips) elec-
tron microscope. Micrographs were taken at a mag-
ni¢cation of 35 000 using 80 kV electrons.
2.10. Colchicinoids £uorescence measurements
Samples of colchicine and colchicinoids 2 and 4
were prepared in water. Vesicles were prepared by
mixing compound 5 or 6 (10 nmol) with the £uid
neutral lipid 8, and compound 7 (10 nmol) was
mixed with the rigid neutral lipid 10, in a 4/1 molar
ratio in chloroform. Solvent was then removed in
vacuo and pure water was added (2.0 ml). Samples
containing 5 and 6 were sonicated in the dark with a
sonication probe for 45 min at room temperature
whereas sonication of 7 was performed at 70‡C. Un-
less otherwise stated, all samples were prepared to
have a ¢nal colchicine or colchicinoid concentration
of 5 WM. Fluorescence measurements were per-
formed in 1 cm quartz cuvettes, with a Jobin Yvon
JY3D spectro£uorimeter.
2.11. X-Ray di¡raction experiments
Samples were analyzed with a Guinier camera
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mounted on a sealed X-ray generator operated at 850
W. Shortly, the X-ray beam was focused with a
quartz monochromator. The specimens were loaded
in a cell equipped with mica windows. The temper-
ature of the cell was monitored by a circulating water
bath in the range 310^60‡C ( þ 1‡C). The X-ray pat-
terns were recorded on photographic ¢lms.
3. Results
3.1. Binding of colchicinoids to tubulin
The binding of colchicinoids 1^4 to pure tubulin
was monitored by £uorescence spectroscopy. Com-
pounds 1 and 2 possess a N-acyl linker on the alka-
loid B-ring; they exhibit a characteristic £uorescence
increase upon binding to tubulin (Fig. 2A) [11,19,42].
Because colchicinoids 3 and 4 have a N-alkyl group
on the B-ring, they exhibit a very small £uorescence
change upon addition of tubulin. This data are in
agreement with the previously reported correlation
between the £uorescence change and the presence
or not of a N-acyl substituent on the B-ring of col-
chicine [11]. However as podophyllotoxin, a well
known competitor of colchicine for the binding to
tubulin, colchicinoids 3 and 4 prevent the binding
of colchicine to tubulin (Fig. 2B). We conclude that
compounds 3 and 4 bind to tubulin at the colchicine
site.
The rate constants for colchicine and colchicinoid
binding to tubulin were derived from the concentra-
tion dependence of the pseudo ¢rst order rate con-
stant of the £uorescence increase. Very similar results
were obtained for colchicine and colchicinoids 1 and
2. Since the £uorescence enhancement observed with
colchicinoids 3 and 4 is very low, the kinetic param-
eters could not be determined accurately for these
compounds and the corresponding experiments
were not carried out.
3.2. Assembly properties of tubulin^colchicinoid
complexes
The tubulin^colchicinoid complexes were found
capable of spontaneous assembly at 37‡C in bu¡er
A containing 10 mM MgCl2 and 1 mM GTP, as
described for tubulin^colchicine complexes [20,43].
Fig. 3 shows typical turbidimetric recordings of the
assembly processes. The self-assembly process of tu-
bulin^colchicinoid complexes exhibits a shorter ini-
tial lag time in the turbidity increase than the tubu-
Fig. 2. Binding of colchicine derivatives to tubulin in competi-
tion with colchicine. (A) Fluorescence change for the formation
of the tubulin^colchicine complexes (R) and the tubulin^colchi-
cinoid complexes (tubulin-1 : b ; tubulin-2 : a ; tubulin-3 or tu-
bulin-4 : E, superposable curves). The solid line is a theoretical
exponential ¢t of the data. Concentration of colchicine and
analogues was 50 WM and of tubulin 3.3 WM. The experiments
were carried out in bu¡er B at 37‡C. Excitation wavelength
was 370 nm; emission wavelength was 460 nm. (B) Inhibition
of colchicine binding to tubulin by colchicinoids 3 and 4. Col-
chicine (100 WM) and the competitor (50 WM; compound 3 : E,
compound 4 : F, podophyllotoxin: O) were added to the tubu-
lin solution (3 WM), then mixed to start the reaction. Bu¡er
conditions are the same as in (A). The R data set corresponds
to the £uorescence recorded in the absence of competitor.
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lin^colchicine complexes, indicating that the free en-
ergy of nucleation is lower. In all cases, the assembly
process is biphasic in a large range of tubulin^colchi-
cinoid concentrations. The extent of turbidity change
per mol of assembled tubulin is larger for tubulin^
colchicinoid than for tubulin^colchicine complexes.
In agreement with the kinetic data, the critical con-
centrations for assembly of tubulin^colchicinoid
complexes is lower than for tubulin (Fig. 4). Values
of 12 WM for tubulin^colchicine, 2.0 WM for tubulin-
1, 2.2 WM for tubulin-2, and 3.8 WM for both tubu-
lin-3 and tubulin-4 were obtained. These data suggest
that the more or less hydrophobic arm attached to
the colchicine core facilitates the interactions be-
tween tubulin^colchicinoid complexes which lead to
self-assembly.
3.3. GTPase activity of tubulin^colchicinoid
complexes
Binding of colchicine to tubulin provides the pro-
tein with a spontaneous slow GTPase activity [14,18],
which appears uncoupled from the polymerization
process. Data, displayed in Table 1, show that tubu-
lin^colchicinoid complexes hydrolyze GTP at a two-
fold faster rate than the tubulin^colchicine complex.
The higher catalytic e⁄ciency of tubulin^colchicinoid
compared to tubulin^colchicine may be attributed to
the greater ability of these complexes to undergo self-
association and is possibly related to the overall hy-
drophobicity of the ligand neighborhood. The con-
clusion of these experiments is that derivatization of
colchicine with an acyl or an alkyl chain does not
impair its binding to tubulin and does not cause
gross changes in the biochemical properties of the
tubulin^colchicine complex.
From these three sets of experiments, it can be
unambiguously concluded that the derivatized alka-
loid fully retains its biological activity towards tubu-
lin. Preliminary binding experiments with the micro-
Fig. 4. Critical concentration for self-assembly of tubulin^col-
chicine and tubulin^colchicinoid complexes. Tubulin^colchicine
(R) and tubulin^colchicinoid complexes (symbols b, a, E, and
F refer to 1^4 respectively) were polymerized at di¡erent con-
centrations, and sedimented at the end of the polymerization
process. The amount of polymerized material in each sample
was determined as described in Section 2.
Fig. 3. Polymerization of the tubulin^colchicine and tubulin^
colchicinoid complexes. Polymerization process was monitored
turbidimetrically at 420 nm under the following conditions:
bu¡er A containing 10 mM MgCl2, 37‡C, 15.0 mM tubulin^
colchicine (R), 14.3 WM tubulin-1 (b), 13.9 WM tubulin-2 (a),
14.0 WM tubulin-3 (E), and 16.0 WM tubulin-4 (F).
Table 1
GTPase activity of the tubulin^colchicinoid complexes
Complex k (min31)
Tubulin 0.012 þ 0.002
Tubulin^colchicine 0.107 þ 0.015
Tubulin-1 0.203 þ 0.011
Tubulin-2 0.209 þ 0.006
Tubulin-3 0.163 þ 0.005
Tubulin-4 0.163 þ 0.005
The kinetic parameters of GTP hydrolysis by the tubulin^col-
chicine and tubulin^colchicinoids complexes were determined at
37‡C in 25 mM MES pH 6.8 (see Section 2).
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tubule component and lipid layers spread from com-
pound 7 however indicated that the protein did not
interact with the lipid ¢lm (data not shown). At ¢rst
sight that result is not consistent with those described
just above. Two possible explanations were pro-
posed, the ¢rst one involving a complete photodegra-
dation of the alkaloid moiety, and the second one
putting forward the hypothesis of some particular
lipid^alkaloid interaction. Each of these two points
has been carefully examined.
3.4. Photoisomerization of colchicine and
lipid-anchored colchicine
Photodegradation of colchicine in solution has
been thoroughly investigated since it was discovered
in 1865 [44]. The degradation products have been
identi¢ed as colchicine isomers and were named K-,
L- and Q-lumicolchicines [37,45,46]. Unlike colchicine,
the photoisomerization products do not bind tubulin
[47^52]. Early studies on the absorption and photo-
chemistry of colchicine solutions have shown that the
rate of the photoisomerization process depends on
the value of the dielectric constant of the solvent
[36,53]. Indeed, although the alkaloid is fairly stable
in water when irradiated, it decomposes slowly in
alcohols and much faster in haloalkanes. This obser-
vation prompted us to investigate the photoisomeri-
zation rate of colchicine when linked to a lipid ma-
trix. We found that isomerization of colchicine in
hexane/ethanol (9/1; v/v) proceeds sevenfold faster
than in water (Fig. 5). When colchicine is anchored
to a lipid, degradation is drastically enhanced and
the £uid neutral colchicinoid-anchored lipid (5) pho-
toisomerizes ¢vefold faster than colchicine in hexane/
ethanol, i.e. 35 fold faster than colchicine in water.
These observations indicate that colchicine behaves
di¡erently in pure water and in presence of lipids and
thus suggest that the alkaloid interacts with the ali-
phatic chains of the lipids. Consequently, all further
experiments involving colchicine and lipids were real-
ized under red light. A new series of binding experi-
ments with tubulin and colchicinoid lipid monolayers
under non-isomerizing conditions however failed and
suggested that the alkaloid might be deeply buried in
between the aliphatic chains of the lipid used. That
point has been addressed through lipid monolayer
experiments, £uorescence measurements, and X-ray
di¡raction studies.
3.5. Monolayer behavior of colchicinoid-anchored
lipids
The accessibility of the colchicine moiety to tubu-
lin in colchicinoid-anchored lipid layers might vary
depending on the conformation of the lipid aliphatic
chains. To tackle that problem, we performed ¢lm
balance experiments.
The surface pressure versus area isotherms of £uid
and rigid colchicinoid-anchored lipids 5^7 are shown
in Fig. 6. The isotherms of the precursor lipid ma-
trices 8 (£uid) and 10 (rigid) are displayed for refer-
ence. As expected, the values for the lift-o¡ area Alo
are much higher for the colchicinoid-anchored lipids
(5^7) than for the corresponding non-derivatized lip-
ids (8 and 10). This clearly indicates that when
present, the colchicine moiety inserts between the
lipids fatty chains. With £uid lipids (5 and 6), the
alkaloid remains partly buried in the chains even at
high surface pressure and, when the monolayers en-
ter the collapse region, the areas per molecule are
still much higher than that recorded with lipid 8
(Table 2). In addition, the As value for the £uid-
Fig. 5. Photoisomerization of colchicine and lipid-anchored col-
chicine in di¡erent solvents. Samples were irradiated at 365 nm
and optical density was measured at Vmax : colchicine in water
(51.07 WM, Vmax = 353 nm, b), methylene chloride (51.07 WM,
Vmax = 345 nm, a), hexane/ethanol (9/1) (51.07 WM, Vmax = 351
nm, F), and 5 in hexane/ethanol (9/1) (50.77 WM, Vmax = 346
nm, E). The horizontal line corresponds to the theoretical resid-
ual absorption after complete photoisomerization.
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charged lipid (6) is found smaller than that for the
neutral one (5). This is due to the protonation of the
amine group in the colchicinoid moiety that makes it
more hydrophilic. Consequently, the alkaloid goes
further into the aqueous phase. In the case of the
rigid colchicinoid-anchored lipid (7), the main-phase
transition plateau [54] appears around 20 mN/m (to
be compared to 9 mN/m for compound 10) due to
some disorder induced by the alkaloid insertion in
the monolayer. Once the lipid enters the crystalline
phase, the alkaloid moiety is progressively expelled
towards the aqueous phase and the monolayer col-
lapses with the same As value as that measured for
the non-derivatized saturated lipid 10, consistent
with a total exclusion of the colchicinoid from the
aliphatic chains region.
Fig. 7. Fluorescence of a steady-state monolayer of colchicinoid-anchored lipids. The micrographs correspond to the £uid neutral col-
chicinoid-anchored lipid (5) incorporating eggPE-£uorescein (1 mol%) spread at the air^water interface at 550 Aî 2/molecule. The bright
regions indicate the liquid expanded phase, while the dark regions correspond to the gas phase, as provided by the identi¢cation in
the literature [58,59]. The thermodynamically unstable ¢lamentous bright regions that form initially (a, 2 min) disappear over an ab-
normally long period of time (b, 12 h). In the same experimental conditions, the £uid lipid 8 reaches the equilibrium state as shown
in b within 5^10 min (data not shown).
Fig. 6. Monolayer behavior of the di¡erent lipid compounds.
Pressure versus area curves were obtained with compounds 5
(^), 7 (- - -), 8 (8) and 10 (.....) spread at the air^water interface
at 21‡C. Compound 6 exhibits a pressure versus area curve that
superimposes on that of 5 except that collapse occurs at 42
mN/m (see Table 2).
Table 2
Surface behavior of the colchicinoid-anchored lipids
Compound Alo (nm2) As (nm2) Zc (mN/m)
5 2.30 0.73 41
6 2.05 0.70 42
7 1.90 0.33 66
8 1.05 0.67 22
9 1.55 0.60 38
10 0.70 0.33 58
Monolayer parameters of compounds 5^10 at the air^water in-
terface were determined at 21‡C. Compressions were carried
out as described in Section 2.
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Accordingly, £uorescence microscopy experiments
show that the £uid colchicinoid-anchored lipid
monolayers (from 5 and 6) are abnormally rigid
and cohesive. Firstly, vigorous streaming normally
observed in £uid monolayers at the air^water inter-
face is drastically reduced with these lipids, and then
sharp images are obtained even with extended expo-
sure times. Secondly, whereas a classical £uid mono-
layer reaches the equilibrium within a few minutes
following complete evaporation of the spreading sol-
vent [54^57], compounds 5 and 6 spread into steady-
state monolayers over several hours (Fig. 7 [58,59]).
We propose that the insertion of colchicine in the
fatty alkyl chains accounts for such a behavior.
The alkaloid inhibits some of the chain molecular
motion, hence the monolayer rigidi¢cation. This in-
terpretation is consistent with another observation,
when colchicine is introduced into the aqueous phase
beneath a preformed lipid monolayer, the surface
pressure varies slowly with time. While a £uid mono-
layer evolves toward a more condensed state (Fig.
8a), a rigid one gives rise to a surface pressure in-
crease (Fig. 8b). As can be seen in Fig. 6, the expel-
ling of colchicine from a saturated ¢lm only occurs at
high surface pressure (above 40^45 mN/m, see the
isotherm obtained for compound 7). Thus at 18
mN/m the surface pressure is not high enough to
e⁄ciently prevent the insertion of the alkaloid in
the monolayer, even though the later is in the crys-
talline phase. Due to the compact organization of the
¢lm, the alkaloid insertion then provokes an increase
in the surface tension. This surprising dual e¡ect of
colchicine on lipid layers depending on whether they
are £uid or rigid is indeed similar to that of choles-
terol, a widespread compound of cell membranes
[60^62].
3.6. Fluorescence measurements on vesicles of
colchicinoid-anchored lipids
Fluorescence of colchicine is extremely low at
room temperature [63]. In polar solvents (dielectric
constant Os 15) £uorescence arises from the immo-
bilization of the alkaloid due to solvent viscosity or
steric hindrance [64]. In apolar solvents, on the other
hand, £uorescence is highly sensitive to the dielectric
constant and increases more than threefold when O
decreases from 15 to 7.5 [64]. Hence, we used the
£uorescence of colchicine to probe the insertion of
the colchicine moiety in the aliphatic chains when
colchicinoid-anchored lipids are displayed at an in-
terface. A high sensitivity CCD camera (100 times as
sensitive as the spectro£uorimeter) failed to detect
any signi¢cant £uorescence signal in monolayers of
the compounds at the air^water interface, even with
integration times extending over 10 min. To increase
the signal over noise ratio, experiments were per-
formed on lipid vesicles.
The £uorescence intensities measured for colchi-
cine and colchicinoids 2 and 4 in aqueous solutions
were found similar, indicating that the structural
modi¢cations of the alkaloid do not drastically a¡ect
its £uorescence properties (Table 3). The measure-
ments realized on vesicles of the colchicinoid-an-
chored lipids 5, 6 and 7 clearly indicate that immo-
bilization of the colchicine moiety at the lipid
interface led to a £uorescence enhancement. More-
Fig. 8. Time-dependent insertion of colchicine into lipid mono-
layers. Compound 8 (a) was spread at the air^water interface
and compressed to 19 þ 0.5 mN/m. the resulting £uid monolayer
appeared quite stable after a short period of time (20 min).
When 0.5 mM colchicine from a 0.5 M stock solution is in-
jected beneath the monolayer (b), the surface pressure slowly
decreases over an extended period of time. During the ¢rst min-
utes, the surface pressure variations are governed by the rate of
mixing of the alkaloid solution to the bulk water in the trough,
and revealed poorly reproducible (data not shown). The same
experiment was realized with compound 10 (F), compressed to
18 þ 0.5 mN/m. The crystalline monolayer obtained is not stable
as evidenced by the initially fast then slower decrease of the
surface pressure. When colchicine is injected beneath the rigid
monolayer (E), the interaction of the alkaloid with the lipid
¢lm provokes an increase of the surface pressure.
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over, that £uorescence enhancement is likely to be
partly reduced by a £uorescence quenching phenom-
enon [65,66]. As a matter of fact, the local surface
concentration of the colchicine moiety on the vesicles
is much higher than the 5 WM considered for the
bulk sample. It is not possible however to make cor-
relations with the results of measurements realized
on colchicine samples at higher concentration (10
and 105 WM) and leading to a complete £uorescence
quenching.1 Assuming that the colchicine moieties
are similarly distributed in the samples (i.e. the local
concentrations of the alkaloid are the same), the dif-
ferences observed in £uorescence intensity can be at-
tributed either to partial immobilization of the alka-
loid structure, or to a di¡erence in the dielectric
properties of the colchicine neighborhood, or to
both of the e¡ects. In all cases, the results are fully
consistent with those of the monolayer study. Indeed,
insertion of the colchicine moiety between the ali-
phatic chains of the lipids both restricts its rotational
relaxation and decreases the local value of the dielec-
tric constant [67^69]. More precisely, the deeper the
position of colchicine in the membrane, the greater
its structural constraint and the lower the value of O,
leading to the higher £uorescence intensity on the
whole. Accordingly the £uid neutral lipid sample
(5) is by far the most £uorescent (Table 3). On the
other hand, the £uorescence intensity measured for
the £uid charged lipid sample (6) was expected to be
intermediate between those for the £uid neutral and
the rigid neutral lipid samples (7). That is not the
case and can be interpreted in terms of di¡erence
in the local dielectric constants. In the experimental
conditions, compound 6 is protonated at the colchi-
cine moiety which thereby is better solvated by water
molecules than in compound 7. The resulting higher
local O value thus causes a decrease in the £uores-
cence intensity of the compound.
3.7. X-ray di¡raction study of lecithin-aqueous phases
in the presence of colchicine
To further investigate the interaction between col-
chicine and lipids, X-ray di¡raction experiments were
realized using dimyristoyl lecithin (DMPC), the ma-
jor constituent of biological membranes. Aqueous
lecithin samples exhibit characteristic phases which
can be easily analyzed by X-ray di¡raction studies.
The structural polymorphism of lecithins mainly de-
pends on the nature of the aliphatic chains (length,
saturation), the concentration of the lipid and the
temperature. To assess the e¡ects of colchicine on
the phase diagram of lecithins, we studied DMPC
samples containing 25% water. Such DMPC samples
exhibit three di¡erent conformations in the temper-
ature range 0^30‡C (LK, PLP and LLP) which have
characteristic X-ray di¡raction patterns [70]. The
transition temperatures are equal to 15 and 24‡C
for LLP-PLP and PLP-LK, respectively. A DMPC sam-
ple containing an equimolar amount of colchicine
displays a similar phase diagram (Fig. 9). The X-
ray di¡raction patterns of DMPC^colchicine mix-
tures show the characteristic re£ections of lamellar
phases plus additional ones. These additional re£ec-
tions are present in the X-ray di¡raction pattern of a
concentrated aqueous colchicine solution, revealing
the presence of colchicine aggregates (Fig. 9d). How-
ever, the two phase transition temperatures are sig-
ni¢cantly lowered. While the second lipid phase tran-
sition temperature (PLP-LK) is slightly shifted by
colchicine (32‡C), the ¢rst transition temperature
(LLP-PLP) is lowered by more than 10‡C. Similar re-
sults have been obtained for lipid^colchine aqueous
Table 3
Fluorescence of colchicine derivatives
Sample Concentration (WM)a Vmax (nm) Intensity (a.u.)b
Colchicine 5.01 421 1.00
Colchicine 10.02 421 0.62
Colchicine 105.80 411 0.05
2 5.03 412 0.92
4 5.30 411 0.95
5c 5.08 412 4.63
6c 5.01 400 1.29
7d 4.98 417 2.20
The insertion of colchicine in between the lipid fatty chains is
acknowledged by an increase in £uorescence intensity.
aConcentration of colchicine or colchicine derivative.
bFluorescence intensities have been normalized (to 1 for colchi-
cine) and are corrected for the discrepancies in concentrations.
cThe sample contains 20% of compound 8.
dThe sample contains 20% of compound 10.
1 A rough estimate of local alkaloid concentration at the sur-
face of liposomes would give 1^2 M.
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Fig. 10. Micrographs of colchicinoid-anchored lipid monolayers. Samples were negatively stained with a 2% uranyl acetate solution.
Prior to incubation with tubulin, the lipid ¢lm spread from 7 appears very smooth and homogeneous (a). When the lipid ¢lm is de-
posited at the surface of a tubulin solution, the protein adsorbs scarcely at the interface (b). This adsorption is not reduced when the
¢lm is incubated with the tubulin^colchicine complex which reveals a purely non-speci¢c electrostatic interaction.
Fig. 9. X-Ray di¡raction patterns of DMPC^colchicine aqueous phases. Equimolecular amounts of colchicine were added to DMPC
samples containing 25% water. After stirring, the samples were let to equilibrate for at least 24 h at 60‡C. The X-ray di¡raction pat-
terns of the DMPC^colchicine samples show the characteristic re£ections of lamellar phases [70], plus additional ones (a: 30‡C;
b: 5‡C; c: 35‡C). These last re£ections are present in the X-ray di¡raction pattern of a colchicine sample lacking DMPC (d: 20‡C).
This indicates that colchicine microcrystalline aggregates are present in the lipid phases. This is further supported by some e¡ect on
the lamellar phase transition. Depending upon the temperature, the lipid lamellar phases have a LLP (a), PLP (b), or LK (c) conforma-
tion. The low angle pattern is enlarged and inserted in b, showing the characteristic re£ections of the PLP phase (*, [70]). The tempera-
tures of the lipid phase transitions are lowered by the presence of colchicine. While the ¢rst transition (LLP-PLP) is lowered by more
than 10‡, the second (LLP-LK) is lowered by a few degrees.
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mixtures with a di¡erent lipid/colchicine molar ratio
(5 and 10, data not shown). This result indicates that
colchicine interacts with the DMPC molecules and
a¡ects the stability of the lecithin-aqueous phases
whatever the organization of the lipid chains may
be (LK, PLP or LLP).
3.8. Interaction between tubulin and
colchicinoid-anchored lipids
No binding of tubulin could be detected to any
one of the colchicine-anchored lipids spread at the
air^water interface, even with extended incubation
times, at high temperature, and under red light
(Fig. 10). Compound 7 spreading into a rigid mono-
layer and thus mechanically expelling the alkaloid
toward the aqueous phase gave the same results as
5 and 6 and could not ¢x the protein. Occasionally
isolated tubulin molecules could be seen on the sur-
face of the monolayer. However, the binding was
most likely aspeci¢c since it could not be inhibited
when colchicine was added to the protein prior to
incubation with the lipid ¢lms. These last pieces of
data demonstrate that when it interacts with lipids,
colchicine is not accessible to tubulin.
4. Discussion
This work has been focused on the interaction of
colchicine with lipid boundaries. All the results con-
vey the view that colchicine interacts tightly with a
hydrophobic neighborhood. This conclusion is at
variance with the one derived from previous ESR
experiments [71]. The colchicine^membrane interac-
tion results in signi¢cant alterations of the properties
of both the alkaloid and the lipid membrane. Such
alterations are likely to a¡ect biological activities of
colchicine that are independent of its interaction with
tubulin and its e¡ect on microtubule dynamics [72^
81].
The general behavior of the alkaloid in a lipid
environment is consistent with its high octanol/water
partition coe⁄cient (12.6) [82]. The direct interaction
of colchicine with the cell membrane has been a sub-
ject of controversy several years ago [83^87] but has
not been investigated into details until very recently
[88]. The results presented here establish that the
alkaloid interacts with lipid layers, whether they are
in the £uid or in the crystalline phase. The associa-
tion of colchicine with lipids in a membrane pro-
vokes a modi¢cation of the mechanical properties
of the membrane. This can be paralleled with the
action of local anesthetics on membrane £uidity
and by the way some studies have reported physio-
logical e¡ects of colchicine similar to those elicited by
anesthetics [89^97].
Certainly one of the most important results in this
work is that colchicine interacting with the lipid
membrane may be unavailable for its cytosolic recep-
tor tubulin. This is clearly demonstrated by the ab-
sence of protein binding to the ¢lms observed in the
electron microscopy experiments. In the case of the
crystalline lipid ¢lm (spread from compound 7)
though the alkaloid is fully displayed in the aqueous
media it does not allow tubulin binding. This rather
unexpected result could be explained considering the
alkaloid lying £at on the lipid ¢lm what might im-
pede its recognition by the protein. Another plausible
explanation would reside in the poorly documented
property of the alkaloid to form dimers or higher
order aggregates in solution [98,99]. Thus it has
been established that in a 15 mM colchicine aqueous
solution, 48% of the alkaloid is involved in the for-
mation of dimers, larger aggregates predominate at
higher concentration. The thermodynamic parame-
ters of the self-association process are not in agree-
ment with the classical picture of hydrophobic inter-
actions and rather correlate with stacking
interactions as calculated for a number of dyes and
bases. Considering the speci¢c area measured for
compound 7 when spread into a monolayer, we can
estimate the local concentration of the alkaloid at the
interface to be around 8.7 M what might de¢nitely
prevent the existence of any monomer available for
protein complexation.2
Our results suggest that when colchicine is used in
vivo, it should primarily widely distribute in the
membranes of cells so most of the alkaloid molecules
are not able to directly interact with tubulin. In a
second step of the drug delivery process, the alkaloid
is slowly released into cytosol being mostly irrever-
2 Volume per alkaloid molecule: V = 0.333=2 = 0.19 nm3. Local
alkaloid concentration: c = 1/(0.19 10324U6.02 1023) = 8.7 M.
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sibly captured by tubulin. Though the concentration
investigated herein is several orders of magnitude
higher than the serum concentration obtained when
a recommended total therapeutic dose of 2 mg of
colchicine is administered to a 70 kg human, it is
likely that our observations re£ect part of the devel-
opment of the alkaloid in the cell. Thus there should
be some clinical implications as colchicine is highly
toxic and the therapeutic margin very narrow (7 mg
colchicine has proved fatal [100]). The picture is in
agreement with the scarce pharmacokinetic informa-
tion on the drug actually available [74,101] and with
the high concentrations excreted in bile [102]. May be
the way colchicine is used in clinical environment at
present should be basically reconsidered. As an ex-
ample, liposomal formulations of colchicine have
been described very recently [103]. However the
true location of the drug was not investigated. The
authors worked on the assumption that the alkaloid
is encapsulated inside the liposomes (e.g. located in
the liposome internal aqueous volume) whereas it is
probably mostly incorporated in the liposomes bi-
layer. No pharmacokinetic data are provided and
clinical e⁄cacy is not claimed what seems to be an-
other argument matching our results.
Even if colchicine widely distributes in membranes,
its soluble part, as low as it can be, may interact with
tubulin. As that interaction is very poorly reversible
it can be supposed that at steady-state in cell a sig-
ni¢cant amount of the alkaloid is bound to the pro-
tein and exerts antimitotic activity. Additional work
is required to determine quantitatively how much
colchicine is in the cytosol within a cell and how
much is membrane-associated. In the end that pro-
vides a picture in which cell membranes serve as a
depot for colchicine, regulating in a passive manner
the intracellular alkaloid concentration. Their phys-
ical properties are therefore altered and the conse-
quences are still to be understood.
Colchicine is a very old drug that comes from
immemorial empirical traditions. As early as in the
Greek mythology, the poisoner Medee used Colchi-
cum extracts to achieve some dark plans and along
history, colchicine has been used in turn as poison
and remedy. After many centuries however, much is
still to be learned about the drug and the ways it
interacts with biological systems.
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